Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

Raf kinases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Raf (42) Apoptosis (3) Autophagy (12) Bcr-Abl (1) c-Kit (5) Caspase (1) EGFR (4) FGFR (7) Isotope-Labeled Compounds (2) JNK (2) MDM-2/p53 (1) MEK (1) p38 MAPK (2) PDGFR (6) Ras (1) RET (7) Src (2) TAM Receptor (1) Tie (6) VEGFR (10)
By Research Areas:	Cancer (50) Cardiovascular Disease (1) Inflammation/Immunology (3) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Raf

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14177

Raf inhibitor 1 3 Publications Verification	Raf	Cancer
Raf inhibitor 1 is a potent *Raf* kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-18227

B-Raf IN 1	Raf	Cancer
B-Raf IN 1 is a potent and selective *B-Raf* kinase inhibitor with an IC₅₀ of 24 nM.

HY-14660A

Dabrafenib Mesylate 50+ Cited Publications GSK2118436 Mesylate; GSK 2118436B	Raf	Cancer
Dabrafenib Mesylate is a potent and selective **Raf kinase inhibitor with IC₅₀*s of 0.6 and 5.0 nM for Raf* ^V600E and c-Raf, respectively.

HY-11004

AZ 628 5+ Cited Publications	Raf Apoptosis	Cancer
AZ 628 is a *pan-Raf* kinase inhibitor with IC₅₀s of 105, 34 and 29 nM for *B-Raf, B-RafV600E, and c-Raf-1*, respectively.

HY-10966

SB-590885 5 Publications Verification	Raf	Cancer
SB-590885 is a potent B-Raf* inhibitor* with K_i of 0.16 nM, and has 11-fold greater selectivity for B-Raf over c-Raf, without inhibition to other human kinases.

HY-146303

*C-RAF* kinase-IN-1**	Others	Cancer
C-RAF kinase-IN-1 (compound 1l) is a potent inhibitor of *C-RAF* kinase with an IC₅₀ of 0.193 μM. C-RAF kinase-IN-1 is a quinoline derivative. C-RAF kinase-IN-1 has the potential for the research of cancer diseases .

HY-142452

*Pan-RAF* kinase inhibitor 1**	Raf	Cancer
Pan-RAF kinase inhibitor 1 is a potent inhibitor of Pan-RAF kinase. Pan-RAF kinase inhibitor 1 regulates MAPK signaling by inhibiting RAF kinase, thereby exerting an effect on the proliferation of RAS-mutant tumor cells. Pan-RAF kinase inhibitor 1 has the potential for the research of cancer diseases (extracted from patent WO2021110141A1, compound 16B) .

HY-14177A

Raf inhibitor 1 dihydrochloride	Raf	Cancer
B-Raf inhibitor 1 dihydrochloride is a potent *Raf* kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-126298

RAF mutant-IN-1	Raf	Cancer
RAF mutant-IN-1 is a **RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC₅₀** values of 21 nM, 30 nM and 392 nM for C-RAF ^340D/Y341D, B-RAF ^V600E and B-RAF ^WT, respectively .

HY-141868

SB-682330A	Raf	Others
SB-682330A is a **Raf kinase** inhibitor.

HY-142820

B-Raf IN 5	Raf	Cancer
B-Raf IN 5 (compound 3b) is a potent inhibitor of protein kinase *B-Raf* with an IC₅₀ of 2.0 nM. B-Raf IN 5 is devoid of binding to the secondary target PXR and resists rapid metabolism. B-Raf IN 6 has the potential for the research of cancer disease .

HY-142830

B-Raf IN 6	Raf	Cancer
B-Raf IN 6 (compound 2c) is a potent inhibitor of protein kinase *B-Raf* with an IC₅₀ of 1.7 nM. B-Raf IN 6 is devoid of binding to the secondary target PXR and resists rapid metabolism. B-Raf IN 6 has the potential for the research of cancer disease .

HY-109574

Raf inhibitor 2	Raf	Cancer
Raf inhibitor 2 is a potent **raf kinase** (IC₅₀<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research .

HY-W013411

(E/Z)-Locostatin (E/Z)-UIC-1005	Others	Cancer
(E/Z)-Locostatin ((E/Z)-UIC-1005) is a racemic of Locostatin. Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice .

HY-W013411A

Locostatin UIC-1005	Others	Cancer
Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin can be used to synthesize chemical probes toward PEBP-proteins. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice .

HY-P1039

R18 PHCVPRDLSWLDLEANMCLP	Raf	Cancer
R18 is a peptide antagonists of 14-3-3, with a K_D of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .

HY-12057

Vemurafenib Maximum Cited Publications 73 Publications Verification PLX4032; RG7204; RO5185426	Raf Autophagy	Cancer
Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of *B-RAF* kinase, with IC₅₀s of 31 and 48 nM for RAF ^V600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .

HY-18817

AFG210	Bcr-Abl FGFR Raf RET VEGFR	Cancer
AFG210 is a potent multi-target kinase inhibitor that primarily inhibits Abl kinase (IC₅₀=330 nM), and also has inhibitory effects on other kinases such as *B-Raf, C-Raf, FGFR-1, RET* and VEGF receptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of Abl kinase .

HY-P1039A

R18 TFA PHCVPRDLSWLDLEANMCLP TFA	Raf	Cancer
R18 TFA is a peptide antagonists of 14-3-3, with a K_D of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .

HY-12787

L-779450 1 Publications Verification	Raf Autophagy	Cancer
L-779450 is a potent and selective *B-Raf* kinase inhibitor with a K_d of 2.4 nM.

HY-159534

Flezurafenibum FlezuRafenib	Raf	Cancer
Flezurafenibum (Flezurafenib) is a rapidly accelerated fibrosarcoma (Raf) kinase inhibitor, with antineoplastic effect .

HY-159508

Brimarafenibum BrimaRafenib	Raf	Cancer
Brimarafenibum (Brimarafenib) is a rapidly accelerated fibrosarcoma (Raf) kinase inhibitor, wtih antineoplastic effect .

HY-15246

Tovorafenib 2 Publications Verification TAK-580; MLN 2480; BIIB-024	Raf	Cancer
Tovorafenib (TAK-580, MLN 2480) is an orally active and selective inhibitor of *pan-Raf* kinase.

HY-12057R

Vemurafenib (Standard)	Raf Autophagy	Cancer
Vemurafenib (Standard) is the analytical standard of Vemurafenib. This product is intended for research and analytical applications. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of *B-RAF* kinase, with IC₅₀s of 31 and 48 nM for RAF ^V600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .

HY-136567

TBAP-001	Raf	Cancer
TBAP-001 (Synthesis 13), extracted from patent WO2015075483A1, is a pan-RAF kinase inhibitor, with an IC₅₀ of 62 nM in BRAF V600E kinase assay .

HY-158027

B-Raf IN 17	Raf VEGFR FGFR	Cancer
B-Raf IN 17 (Compound 8e) is a potent and orally active type II multi-kinase inhibitor. B-Raf IN 17 exhibits potent cellular-level suppression of BRAF_WT, VEGFR-2, and FGFR-1 in A375 cell line, with IC₅₀ values of 0.02, 0.18 and 1.65 μM, respectively. B-Raf IN 17 can be used for the research of cancer .

HY-19343

XL-281 BMS-908662	Raf	Cancer
XL-281 (BMS-908662) is an orally active inhibitor for RAF kinase, with IC₅₀s of 2.6, 4.5 and 6 nM, for CRAF, B-RAF, and B-RAFV600E, respectively. XL-281 exhibits antitumor activity .

HY-18957A

rel-Lifirafenib rel-BGB-283	Others	Cancer
rel-Lifirafenib (rel-BGB-283) is the relative configuration of Lifirafenib (HY-18957). Lifirafenib is a potent Raf Kinase and EGFR inhibitor .

HY-13343

ZM 336372 2 Publications Verification	Raf Apoptosis	Cancer
ZM 336372 is a potent inhibitor of the protein kinase *c-Raf. The IC₅₀* value is 0.07 μM in the standard assay, which contains 0.1 mM ATP.

HY-18957

Lifirafenib 1 Publications Verification BGB-283	EGFR Raf	Cancer
Lifirafenib (BGB-283) is a novel and potent *Raf* Kinase and EGFR inhibitor with IC₅₀ values of 23 and 29 nM for recombinant BRaf ^V600E and EGFR, respectively.

HY-12057S

Vemurafenib-d5	Isotope-Labeled Compounds Raf Autophagy	Cancer
Vemurafenib-d₅ is the deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].

HY-12057S1

Vemurafenib-d7 PLX4032-d₇; RG7204-d₇; RO5185426-d₇	Isotope-Labeled Compounds Raf Autophagy	Cancer
Vemurafenib-d₇ is deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].

HY-18957B

Lifirafenib maleate BGB-283 maleate	EGFR Raf	Others Cancer
Lifirafenib (BGB-283) maleate is a novel and potent *Raf* Kinase and EGFR inhibitor with IC₅₀ values of 23 and 29 nM for recombinant BRaf ^V600E and EGFR, respectively .

HY-18832

AWL-II-38.3	Others	Cancer
AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf .

HY-10331

Regorafenib 55+ Cited Publications BAY 73-4506	VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie	Cancer
Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and *Raf-1*, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .

HY-10331A

Regorafenib monohydrate 55+ Cited Publications BAY 73-4506 monohydrate	VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie	Cancer
Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and *Raf-1*, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .

HY-10331B

Regorafenib mesylate BAY 73-4506 mesylate	VEGFR PDGFR RET Raf c-Kit FGFR Autophagy Tie	Cancer
Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and *Raf-1*, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity .

HY-10331S1

Regorafenib-13C,d3 BAY 73-4506-¹³C,d₃	VEGFR Autophagy PDGFR Raf RET	Cancer
Regorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.

HY-18652A

Avutometinib potassium Ro 5126766 potassium; CH5126766 potassium	Raf MEK	Cancer
Avutometinib (CH5126766) (potassium) is a *RAF/MEK* clamp that potently inhibits *RAF/MEK* kinase activity and induces dominant negative *RAF-MEK* complexes preventing phosphorylation of MEK by ARAF, BRAF and CRAF. Avutometinib (potassium) shows anti-proliferative potency across tumor cell lines carrying KRAS mutations including PDAC cell lines. Avutometinib (potassium) induces tumor inhibition and increases survival in a KRAS/p53 pancreatic cancer mouse model. Avutometinib (potassium) is promising for research of low-grade-serous-ovarian-carcinoma (LGSOC), ovarian cancer and pancreatic ductal adenocarcinoma (PDAC) .

HY-107779

BI-882370	Raf	Cancer
BI-882370 is a potent and selective *RAF* kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAF ^V600E-mutant, the WT BRAF and CRAF kinases with IC₅₀s of 0.4, 0.8, and 0.6 nM, respectively. BI-882370 also inhibits SRC family kinases .

HY-164530

SKLB646	Src VEGFR Raf p38 MAPK	Cancer
SKLB646 is an orally active multi-target kinase inhibitor. SKLB646 shows significant inhibitory effects on SRC and VEGFR2 with IC₅₀ values ??of 0.002 μmol/L and 0.012 μmol/L, respectively. SKLB646 also shows significant inhibitory effects on *B-Raf* and *C-Raf* with IC₅₀ values ??of 0.022 μmol/L and 0.019 μmol/L, respectively. SKLB646 inhibits the activation of the SRC signaling pathway and blocks the MAPK signaling pathway by inhibiting *Raf* kinase. In addition, SKLB646 can inhibit the proliferation, migration and invasion of human umbilical vein endothelial cells (HUVEC) to inhibit tumor-induced angiopoietic formation. SKLB646 shows significant anti-proliferative and anti-survival activities against triple-negative breast cancer (TNBC) cell lines .

HY-117658

GSK-114	Others	Cardiovascular Disease
GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC₅₀= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC₅₀= 1 µM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue .

HY-P10438

Tat-braftide	Raf	Cancer
Tat-braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by Tat-braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of *RAF* kinase in MAPK signaling pathway and for the study of BRAF mutant cancers .

HY-10331R

Regorafenib (Standard)	VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie	Cancer
Regorafenib (Standard) is the analytical standard of Regorafenib. This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and *Raf-1*, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .

HY-10331AR

Regorafenib monohydrate (Standard)	VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie	Cancer
Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate). This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .

HY-116664

DPQZ	Apoptosis Ras Raf Caspase	Cancer
DPQZ is an anti-tubulin agent that inhibits cell separation and induces cell cycle arrest at the G2/M phase. In addition, DPQZ induces caspase-dependent apoptosis of HSC-3 cells by inhibiting *Ras/Raf* and activating MAP kinase. DPQZ can be used in the study of oral cancer .

HY-135216

Antiproliferative agent-54	Src VEGFR Raf EGFR	Cancer
Antiproliferative agent-54 (Compound 6z) is the inhibitor for multiple kinases, such as ABL WT, *B-RAF, EGFR, HCK, LYN A* and SRC with IC₅₀ of 6-50 nM. Antiproliferative agent-54 inhibits proliferation of several cancer cell, inhibits HUVEC and HepG2, with EC₅₀ of 34 and 38 nM. Antiproliferative agent-54 exhibits good pharmacokinetic characteristics in rats .

HY-11010

AS601245 5+ Cited Publications	JNK	Neurological Disease Inflammation/Immunology Cancer
AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC₅₀s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties .

HY-11010A

AS601245 TFA	JNK	Neurological Disease Inflammation/Immunology Cancer
AS601245 TFA is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC₅₀s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 TFA exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties .

HY-N3634

Corylifol C	EGFR TAM Receptor Tie	Cancer
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

Cat. No.	Product Name

HY-L196

Protein Kinase Compound Library

2,930 compounds

Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR.

MCE designs a unique collection of 2,930 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

Cat. No.	Product Name	Target	Research Area